C1 3. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the primary effector molecules is a TNF family member.

C2 5. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the primary effector molecules is an anti-angiogenic factor.

C3 7. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.

C4 9. (Amended) The attenuated tumor targeted bacteria of claim 2, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.

11. (Amended) The attenuated tumor targeted bacteria of claim 2, wherein at least one of the primary effector molecules is hemolysin, verotoxin, CNF1, CNF2, or PMT.

12. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

C5 13. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the secondary effector molecules is an immunomodulating agent, an anti-tumor protein, a pro-drug converting enzyme, an antisense molecule, a ribozyme, or an antigen.

14. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein the attenuated tumor-targeted bacteria is *Salmonella*.

C6 16. (Amended) The attenuated tumor-targeted bacteria of claim 2, wherein at least one of the secondary effector molecule is a bacteriocin release factor (BRP).

C7 27. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is a TNF family member.

C8 29. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is an anti-angiogenic factor.

C9 31. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.

C10 33. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.

35. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is hemolysin, verotoxin, CNF1, CNF2, or PMT.

36. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

C11

37. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the secondary effector molecules is an immunomodulating agent, an anti-tumor protein, a pro-drug converting enzyme, an antisense molecule, a ribozyme, or an antigen.

38. (Amended) The pharmaceutical composition of claim 26, wherein the attenuated tumor-targeted bacteria is *Salmonella*.

C12 40. (Amended) The pharmaceutical composition of claim 26, wherein at least one of the secondary effector molecules is a bacteriocin release factor (BRP).

C13 50. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is a TNF family member.

C14 52. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is an anti-angiogenic factor.

C15 54. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is a bacteriocin family member with the proviso said bacteriocin is not BRP.

C16 56. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is a tumor inhibitory enzyme.

58. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is hemolysin, verotoxin, CNF1, CNF2 or PMT.

59. (Amended) The method of claim 49, wherein at least one of the primary effector molecules is derived from an animal, plant, bacteria, or virus.

C17 60. (Twice Amended) The method of claim 49, wherein at least one of the secondary effector molecules is an anti-tumor protein, an immunomodulating agent, a pro-drug converting enzyme, an antisense molecule, a ribozyme, or an antigen.

61. (Amended) The method of claim 49, wherein the attenuated tumor-targeted bacteria is *Salmonella*.